Data Sheet (Cat.No.T6668)

TargetMol

SGC-CBP30

Chemical Properties



CAS No. : 1613695-14-9

Formula: C28H33ClN4O3

Molecular Weight: 509.04

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).
Targets(IC50)	Epigenetic Reader Domain,Histone Acetyltransferase
In vivo	SGC-CBP30 exhibits moderate cytotoxicity in U2OS and HeLa cells.

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: 93 mg/mL (182.7 mM),Sonication is recommended. DMSO: 247.5 mg/mL (486.21 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.48 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9645 mL	9.8224 mL	19.6448 mL
5 mM	0.3929 mL	1.9645 mL	3.929 mL
10 mM	0.1964 mL	0.9822 mL	1.9645 mL
50 mM	0.0393 mL	0.1964 mL	0.3929 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Structural Genomics Consortium
Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity. Cancer Immunology Research. 2022, 10(1): 87-107.
Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity[J]. bioRxiv. 2021
Wellinger L C, Hogg S J, Newman D M, et al. Bet inhibition enhances TNF-mediated antitumor immunity. Cancer Immunology Research. 2022, 10(1): 87-107
Gendarme M, Baumann J, Ignashkova T I, et al. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1[J]. Molecular biology of the cell. 2017 Dec 15;28(26):3756-3772.
Gendarme M, Baumann J, Ignashkova T I, et al. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1. Molecular Biology of the Cell. 2017 Dec 15;28(26):3756-3772
Liu L, Deng P, Liu S, et al.Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.Cell Death & Disease.2023, 14(8): 513.
Pan X, Zhang W, Wang L, et al.KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer. Molecular Oncology.2023